Activaero has announced that it will collaborate with Chiesi Farmaceutici on an inhaled treatment for cystic fibrosis that would deliver a Chiesi drug using Activaero’s FAVORITE (Flow And Volume Regulated Inhalation Technology) system. Financial details were not disclosed. According to Activaero, the initial portion of the collaboration should be complete by the end of 2013.
Activaero CEO and Founder Gerhard Scheuch commented, “This exciting research collaboration represents further validation for our proprietary FAVORITE inhalation approach by one of the pioneers in the respiratory arena. We are highly optimistic that this program can provide a significantly improved treatment solution for cystic fibrosis, a detrimental disease with a high unmet medical need.”
Chiesi VP R&D Director Paolo Chiesi added, “The FAVORITE inhalation approach is highly promising to achieve optimal lung deposition rates with lower drug doses and, ultimately, a better therapeutic outcome in the treatment of Cystic Fibrosis. We are looking forward to work with our new partner Activaero on this promising project.”
Read the Activaero press release.
